<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1 </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> formation induced by electrical stimulation of the carotid artery was investigated in anesthetized rabbits and rats </plain></SENT>
<SENT sid="2" pm="."><plain>Occlusive Grade III <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were produced consistently in 34 <z:mpath ids='MPATH_458'>normal</z:mpath> New Zealand rabbits and 58 untreated <z:mp ids='MP_0001189'>albino</z:mp> Wistar rats </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> formation was monitored continuously in some of the animals with a magnetic flowmeter or a thermistor probe applied on the carotid </plain></SENT>
<SENT sid="4" pm="."><plain>2 </plain></SENT>
<SENT sid="5" pm="."><plain>The usefulness of the model for the screening of drugs was tested by treating the animals with <z:chebi fb="8" ids="10033">warfarin</z:chebi>, <z:chebi fb="5" ids="28304">heparin</z:chebi>, prostacyclin (<z:chebi fb="0" ids="15552">PGI2</z:chebi>), dihydroprostacyclin (DiHPGI2), <z:chebi fb="0" ids="15544">prostaglandin E1</z:chebi> (<z:chebi fb="0" ids="15544">PGE1</z:chebi>), and <z:mp ids='MP_0002515'>prostaglandin D2</z:mp> (<z:mp ids='MP_0002515'>PGD2</z:mp>) </plain></SENT>
<SENT sid="6" pm="."><plain>3 </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the drugs except <z:chebi fb="8" ids="10033">warfarin</z:chebi> were infused continuously into the venous circulation during the entire experimental period at a rate of 0.2 ml/min </plain></SENT>
<SENT sid="8" pm="."><plain>4 </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> (10 mg/kg), administered by gavage 24 h before the experiment, prevented <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, as did <z:chebi fb="5" ids="28304">heparin</z:chebi> iv (greater than 34 U/kg) </plain></SENT>
<SENT sid="10" pm="."><plain>5 </plain></SENT>
<SENT sid="11" pm="."><plain>Of the four platelet antiaggregatory <z:chebi fb="11" ids="26333">prostaglandins</z:chebi> tested, <z:chebi fb="0" ids="15552">PGI2</z:chebi> was the most potent inhibitor of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and DiHPGI2 the least active, as evaluated by visual inspection of stimulated arterial segments which were excised 30 min (rabbits) or 15 min (rats) after the stimulation was stopped </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="15552">PGI2</z:chebi> was less active in rats than in rabbits (Threshold Protective Dose ratio ca </plain></SENT>
<SENT sid="13" pm="."><plain>4:1) </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="0" ids="15544">PGE1</z:chebi> and <z:mp ids='MP_0002515'>PGD2</z:mp> showed intermediate activity in both animal models </plain></SENT>
</text></document>